Reports Q3 revenue $24B, consensus $23.76B. “Johnson & Johnson delivered another strong performance in the third quarter fueled by the depth and strength of our portfolio and significant progress across our pipeline,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “With a sharpened focus on the six priority areas of Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision, Johnson & Johnson is in a new era of accelerated growth and innovation, with pioneering treatments that will continue to transform lives.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson Stock (JNJ) Falters Ahead of Earnings Release as Cancer Therapy Gets Warning Label
- Notable companies reporting before tomorrow’s open
- Ardelyx appoints Hohenleitner as Chief Financial Officer
- Protagonist Therapeutics price target raised to $112 from $72 at BMO Capital
- Options Volatility and Implied Earnings Moves This Week, October 14 – October 17, 2025